KEY TAKEAWAYS
- The aim was to assess PROs to understand the impact of CART therapy on QoL.
- The study confirmed that tracking PROs in CART therapy is feasible and informative.
Chimeric antigen receptor T-cell (CART) therapy has demonstrated clinical efficacy in treating refractory and relapsed large B-cell lymphomas. However, it is linked with significant acute and long-term toxicities.
Amaris Balitsky and the team aimed to assess the patient perspective by evaluating health-related quality of life (HRQoL) through patient-reported outcomes (PROs) at multiple time points over 1 year.
Researchers followed patients eligible for standard CART therapy (tisagenlecleucel) to evaluate its feasibility. Using the FACT-Lym questionnaire, they collected demographic data and disease characteristics while assessing HRQoL.
The HRQoL was measured at baseline and then at 1, 3, 6, and 12 months post-therapy. The FACT-Lym tool covered various aspects of well-being, including physical, social, emotional, and functional domains, along with a specific lymphoma subscale.
The results indicated that out of 35 patients approached, 34 consented to participate, but 2 could not receive their infusion due to disease progression. The group was 50% female, with a median age of 62 (range 23-77).
At baseline, 29 patients (91%) completed the FACT-Lym assessment, and 20 out of 21 (95%) eligible patients completed the 12-month follow-up. Additionally, 52% of patients completed all 4 post-baseline assessments. The study included exploratory analyses of changes in FACT-Lym scores.
The study concluded that measuring longitudinal PROs in patients undergoing CART therapy is feasible.These findings will guide future research assessing the patient’s perspective on CART therapy.
The study was funded by Freeburne Banting Foundation.
Source: https://pubmed.ncbi.nlm.nih.gov/39123197/
Balitsky A, Pond GR, Davies GA, et al. (2024). “Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy.” BMC Cancer. 2024 Aug 9;24(1):984. doi: 10.1186/s12885-024-12574-2. PMID: 39123197; PMCID: PMC11312407.
